Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 15/20 | 0.54 |
| ▸ | CDK2 | P24941 | 15/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 15/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331829 | 0.87 | CCNA2 (0.42) | CCNA2CDK2CCNA1GAAIGF1R | |
| SCHEMBL214661 | 0.79 | GAA (0.49) | GAAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL214000 | 0.78 | CCNA2 (0.61) | CCNA2CDK2CCNA1 | |
| SCHEMBL14222316 | 0.78 | GAA (0.54) | GAAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL215229 | 0.77 | MAPT (0.63) | GAAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL213976 | 0.77 | MAPT (0.71) | GAAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL215825 | 0.77 | MAPT (0.57) | GAAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL215408 | 0.77 | GAA (0.49) | GAAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL214865 | 0.76 | GAA (0.47) | GAAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL213885 | 0.76 | GAA (0.48) | GAAKDM4EALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | CCNA2 776/4885CDK2 67/4885CCNA1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.